Ensysce Biosciences, Inc.
corporate_fare Company Profile
Ensysce Biosciences, Inc. (NASDAQ:ENSC) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 34 items for ENSC at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-18, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for ENSC spans DEFA14A, 10-Q, DEF 14A, 8-K.
Recent high-impact activity:
- Ensysce Proxy Supplement: Brokers Gain Discretionary Votes on Reverse Split; Staged Meeting Possible
- Ensysce Q3 Loss of $4.52/Share Blows Past 12-Cent Consensus as Revenue Jumps 342%
- Ensysce 10-Q: $29.7M Cash, $82.3M Q3 Loss, Going-Concern Warning and MHRA Setback on CY200
- Ensysce Sets Dec 14 Vote on 358.3M-Share Series C Conversion, Reverse Split and Share Increase
- Ensysce Ends Q3 With $29.7M Cash, But MHRA Wants More Data on Lead CRPS Program
Financial Snapshot
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 88,607 shares in ENSC as of the October 30, 2026 settlement, a 70.8% decrease from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 13.2% of ENSC volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for ENSC, detected from its recent SEC filings.
Resale S-3 Covers 433.9M Shares · Overhang Is Roughly 22x Outstanding
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →